| Literature DB >> 35821638 |
Tianxiang Tu1, Zongming Song2, Xiaoyu Liu1, Shengxing Wang3, Xiaoxue He1, Haitao Xi4, Jiahua Wang1, Tong Yan1, Haoran Chen1, Zhenwu Zhang5, Xiujuan Lv1, Jineng Lv1, Xiu-Feng Huang4, Junzhao Zhao4, Chao-Po Lin5, Caixia Gao6, Jinwei Zhang7, Feng Gu8.
Abstract
Adenine base editors (ABEs) are novel genome-editing tools, and their activity has been greatly enhanced by eight additional mutations, thus named ABE8e. However, elevated catalytic activity was concomitant with frequent generation of bystander mutations. This bystander effect precludes its safe applications required in human gene therapy. To develop next-generation ABEs that are both catalytically efficient and positionally precise, we performed combinatorial engineering of NG-ABE8e. We identify a novel variant (NG-ABE9e), which harbors nine mutations. NG-ABE9e exhibits robust and precise base-editing activity in human cells, with more than 7-fold bystander editing reduction at some sites, compared with NG-ABE8e. To demonstrate its practical utility, we used NG-ABE9e to correct the frequent T17M mutation in Rhodopsin for autosomal dominant retinitis pigmentosa. It reduces bystander editing by ∼4-fold while maintaining comparable efficiency. NG-ABE9e possesses substantially higher activity than NG-ABEmax and significantly lower bystander editing than NG-ABE8e in rice. Therefore, this study provides a versatile and improved adenine base editor for genome editing.Entities:
Keywords: ABE; bystander effect; engineering; gene therapy; genome editing
Mesh:
Substances:
Year: 2022 PMID: 35821638 PMCID: PMC9481987 DOI: 10.1016/j.ymthe.2022.07.010
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 12.910